Clinical trials in Vienna – page 26

838 clinical trials in Vienna, Austria across 10 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Vienna at a glance

838

clinical trials

Research sites10

Quick filters

838 trials in Vienna

Open in trial search

Tuberous sclerosis complex

Recruiting

Study on the Effects of Sirolimus and Drug Combination for Children Under 4 Months with Tuberous Sclerosis Complex

Registered drugNo placebo

Study on the Effects of Sirolimus and Drug Combination for Children Under 4 Months with Tuberous Sclerosis Complex

Registered drugNo placebo

Austria

Participants:0–17 years
Substances:Carbamazepine
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Breast cancer+2

Recruiting

Long-term Safety Study of Niraparib for Patients with Advanced Ovarian, Breast, or Prostate Cancer Who Completed a Previous Niraparib Study

Registered drugNo placebo

Long-term Safety Study of Niraparib for Patients with Advanced Ovarian, Breast, or Prostate Cancer Who Completed a Previous Niraparib Study

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Niraparib Tosilate Monohydrate
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Acute lymphocytic leukaemia+4

Recruiting

Study on Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine for Children with Relapsed or Refractory Blood Cancer

Registered drugNo placebo

Study on Trametinib, Dexamethasone, Cyclophosphamide, and Cytarabine for Children with Relapsed or Refractory Blood Cancer

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years
Substances:Trametinib
Sponsor:Princess Maxima Center For Pediatric Oncology

Contact Research Centre

Pulmonary arterial hypertension

Recruiting

Study on the Effectiveness and Safety of Treprostinil and Drug Combination for Patients with Pulmonary Arterial Hypertension (Group I)

Registered drugNo placebo

Study on the Effectiveness and Safety of Treprostinil and Drug Combination for Patients with Pulmonary Arterial Hypertension (Group I)

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Treprostinil
Sponsor:Aop Orphan Pharmaceuticals GmbH

Contact Research Centre

Generalised tonic-clonic seizure+1

Recruiting

Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

InvestigationalNo placebo

Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

InvestigationalNo placebo

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Azetukalner
Sponsor:Xenon Pharmaceuticals Inc.

Contact Research Centre

Study Comparing Odronextamab with Rituximab and Chemotherapy for Patients with Untreated Follicular Lymphoma

Recruiting

Registered drugNo placebo

Study Comparing Odronextamab with Rituximab and Chemotherapy for Patients with Untreated Follicular Lymphoma

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Lung transplant rejection

Recruiting

Study on the Effectiveness of Belumosudil and Azithromycin for Adults with Chronic Lung Rejection After Lung Transplant

Registered drug

Study on the Effectiveness of Belumosudil and Azithromycin for Adults with Chronic Lung Rejection After Lung Transplant

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Belumosudil Mesilate
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Chronic lymphocytic leukaemia

Recruiting

Study on Zanubrutinib, Tislelizumab, and Sonrotoclax for Patients with Richter Transformation (a type of lymphoma)

InvestigationalNo placebo

Study on Zanubrutinib, Tislelizumab, and Sonrotoclax for Patients with Richter Transformation (a type of lymphoma)

InvestigationalNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Tislelizumab
Sponsor:University Of Cologne

Contact Research Centre

Plasma cell myeloma

Recruiting

Study on Monitoring Untreated Multiple Myeloma in Patients Using Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone or a New Drug Combination

Registered drugNo placebo

Study on Monitoring Untreated Multiple Myeloma in Patients Using Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone or a New Drug Combination

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Contact Research Centre

Chronic lymphocytic leukaemia recurrent

Recruiting

Study on Venetoclax and Obinutuzumab for Adults with Recurring Chronic Lymphocytic Leukemia

Registered drugNo placebo

Study on Venetoclax and Obinutuzumab for Adults with Recurring Chronic Lymphocytic Leukemia

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Hormone-dependent prostate cancer+1

Recruiting

Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

Registered drugNo placebo

Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Gozetotide
Sponsor:Novartis Pharma AG

Contact Research Centre

Hereditary angioedema with C1 esterase inhibitor deficiency

Recruiting

Study on the Safety of Long-Term Use of Deucrictibant for Treating Hereditary Angioedema Attacks in Patients with C1-Inhibitor Deficiency

Registered drug

Study on the Safety of Long-Term Use of Deucrictibant for Treating Hereditary Angioedema Attacks in Patients with C1-Inhibitor Deficiency

Registered drug

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Deucrictibant
Sponsor:Pharvaris Netherlands B.V.

Contact Research Centre

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in Vienna

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on innovative treatments for various cancer types, including pancreatic ductal adenocarcinoma, gastric cancer, and non-small cell lung cancer. Studies evaluating new therapeutic approaches for breast cancer and multiple myeloma are also underway.

Advanced Cancer Therapies
Targeted Treatment Approaches
Immunotherapy Studies

Research includes evaluation of novel drug combinations and immunotherapy approaches for improved patient outcomes.

02 Neuropsychiatric Studies

Investigations into major depression and its treatment mechanisms, including studies on dopamine synthesis and antidepressant effectiveness. Research examines innovative therapeutic approaches using ketamine and other compounds.

Depression Treatment
Neuroimaging Research
Therapeutic Mechanisms

Focus on understanding brain activation patterns and treatment responses in psychiatric conditions.

03 Autoimmune and Inflammatory Conditions

Research on plaque psoriasis, rheumatic diseases, and Sjögren's syndrome. Studies evaluate new biological therapies and treatment approaches for chronic inflammatory conditions.

Novel Therapeutic Agents
Disease Modification
Long-term Treatment Outcomes

Emphasis on developing targeted therapies for improved disease management and patient quality of life.

Back to Austria All countries